GoodRx reports on tracking prescription fills for flu and COVID-19 treatments, revealing seasonal trends and insurance coverage disparities.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Infant protection against respiratory syncytial virus (RSV) by maternal RSV vaccination or receipt of RSV monoclonal antibody ...

Under the 2024 schedule, which has been discontinued, babies could have received anywhere from 12 to 30 shots before their second birthday ...

As the 'crunchy mom' movement swells, it is emblematic of a mainstream embrace of vaccine skepticism and a broader lack of ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Amid a surprisingly severe flu season and a Covid-19 resurgence, those highly contagious respiratory illnesses are drawing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

A large Centers for Disease Control and Prevention study suggests that US school-aged children diagnosed as having long COVID ...

Following the CDC’s downgrade of the childhood vaccination schedule, pediatricians are warning it could have impacts on ...